Jiangsu Hengrui Medicine Enters into Research Agreement with The University of Texas MD Anderson Cancer Center to Advance Immunotherapy and Precision Medicine for Cancer Treatment
May 03, 2016 at 09:09 am EDT
Jiangsu Hengrui Medicine Co., Ltd. and The University of Texas MD Anderson Cancer Center (MD Anderson) have entered into a research agreement to advance cancer treatment. The 3-year agreement for translational research brings together the scientific and clinical capabilities of MD Anderson and Jiangsu Hengrui Medicine to develop rational combination therapies and personalized medicines as well as to identify new treatment opportunities, especially in the field of immuno-oncology.